New funding supports the company's path forward. OncoZenge has received investment capital from Yangtian Bio-Pharmaceutical. #OncoZenge #LifeScience

OncoZenge advances its BupiZenge program by submitting a Phase III application in Europe, unlocking the third tranche of an SEK 30.2 million investment. The company resolved on a directed share issue to Sichuan Yangtian to fund the trial. #OncoZenge #biotech

OncoZenge AB Partners with UCLA to Enhance Patient Engagement in Pain Management Research OncoZenge AB has teamed up with UCLA to launch a patient engagement study aimed at improving management of oral mucositis pain linked to cancer treatments.

OncoZenge AB Partners with UCLA to Enhance Patient Engagement in Pain Management Research #Sweden #Stockholm #OncoZenge #BupiZenge #UCLA_Health

Grazie mille, nostra famiglia Molteni Farmaceutici, for uniting with OncoZenge! Your vibrant Italian passione and spirito di famiglia inspire us. Together, we’ll deliver hope and healing -un onore grandissimo to collaborate with such a dedicated team!

#OncoZenge

oncozenge.se/pressrelease...

Presentation på lifesciencedagen!
#OncoZenge

Trevlig helg!

#finanstwitter

youtu.be/qNw1El-f9ew?...

Ska moderera lite under life science-dagen i eftermiddag. Har ni några frågor ni tycker jag borde ställa #Bioarctic #Saniona #Alzinova #Oncozenge #fintwitt

lifesciencedagen.se